Post

Cystic fibrosis: global clinical trials landscape and treatments

Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene, affecting chloride and bicarbonate transport in …

EC approves Celltrion’s Omlyclo for allergic conditions

The European Commission (EC) has approved Celltrion’s Omlyclo (CT-P39) - the first and only omalizumab biosimilar for reference product Xolair …

Biocon and Handok link to commercialise Liraglutide in South Korea

Indian biopharmaceutical company Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South …

Magazine: Lula’s progress plan for Brazil: a year on

Almost one year ago, Brazilian president Lula da Silva assembled the first South American summit in nearly a decade to …

Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics

Boehringer Ingelheim has bought a preclinical oncology asset from long-time collaborator OSE Immunotherapeutics, in addition to expanding the scope of …